TGFB1 and neoplasm: The consequence of this is a reduction in the secretion of TGF-β and IL-10, an increase in type I interferon levels (which activates NK cells, DCs, CD4+ T cells, and CD8+ T cells), stimulation of NK cells, and augmentation of anti-tumor immunity (191, 192).